Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito
- PMID: 24990161
- PMCID: PMC4090183
- DOI: 10.1186/1471-230X-14-116
Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito
Abstract
Background: The incidence and severity of gastroesophageal reflux disease (GERD) in Japan tends to increase in elderly women. Rikkunshito (RKT), a traditional Japanese medicine, acts as a prokinetic agent and improves gastric emptying and gastric accommodation. Our previous prospective randomized placebo-controlled study showed that RKT combined with a standard-dose of rabeprazole (RPZ) significantly improved the acid-related dysmotility symptoms (ARD) in elderly patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD). This study aimed to evaluate clinical characteristics of elderly PPI-refractory NERD patients with ARD symptoms who responded to RKT.
Methods: Two hundred forty-two patients with PPI-refractory NERD were randomly assigned to 8 weeks of either RPZ (10 mg/q.d.) + RKT (7.5 g/t.i.d.) (RKT group) or RPZ + placebo (PL group). Among them, 95 were elderly (≥65 years) with ARD (RKT group: n = 52; PL group: n = 43). We analyzed the changes using the 12 subscale score of frequency scale for the symptoms of GERD (FSSG) and 15 items of the Gastrointestinal Symptom Rating Scale at 4 and 8 weeks and compared the therapeutic efficacy between the 2 groups.
Results: There were no marked differences in baseline demographic or clinical characteristics in the 2 groups except for rate of current smoking. The FSSG score (mean ± SD at 0, 4, and 8 weeks) in both the RKT (16.0 ± 7.0; 9.9 ± 8.4; 7.0 ± 6.4) and PL (15.1 ± 6.4; 10.9 ± 6.7, 11.1 ± 8.5) groups significantly decreased after treatment. However, the degree of improvement of total and ARD scores of FSSG after the 8-week treatment was significantly greater in the RKT group than in the PL group. Combination therapy with RKT for 8 weeks showed significant improvement in 3 subscale scores (abdominal bloating, heavy feeling in stomach and sick feeling after meals) of the ARD domain and 1 subscale score (heartburn after meals) of the reflux symptom domain.
Conclusions: RKT may be useful for improving GERD symptoms in elderly PPI-refractory NERD patients with ARD. Thus, RKT was particularly effective for resolving postprandial GERD symptoms (heavy feeling in stomach, sick feeling, and heartburn after meals).
Trial registration: (UMIN000005880).
Figures



Similar articles
-
A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.J Gastroenterol. 2014 Oct;49(10):1392-405. doi: 10.1007/s00535-013-0896-9. Epub 2014 Feb 18. J Gastroenterol. 2014. PMID: 24535455 Clinical Trial.
-
Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.J Gastroenterol. 2012 Mar;47(3):284-92. doi: 10.1007/s00535-011-0488-5. Epub 2011 Nov 15. J Gastroenterol. 2012. PMID: 22081052 Clinical Trial.
-
Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.J Gastroenterol. 2011 Nov;46(11):1273-83. doi: 10.1007/s00535-011-0446-2. Epub 2011 Aug 24. J Gastroenterol. 2011. PMID: 21861141 Clinical Trial.
-
A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.J Gastroenterol Hepatol. 2024 May;39(5):796-805. doi: 10.1111/jgh.16475. Epub 2024 Jan 23. J Gastroenterol Hepatol. 2024. PMID: 38263507
-
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.J Gastroenterol. 2016 Aug;51(8):751-67. doi: 10.1007/s00535-016-1227-8. Epub 2016 Jun 21. J Gastroenterol. 2016. PMID: 27325300 Review.
Cited by
-
Pharmacokinetic Profiles of Active Ingredients and Its Metabolites Derived from Rikkunshito, a Ghrelin Enhancer, in Healthy Japanese Volunteers: A Cross-Over, Randomized Study.PLoS One. 2015 Jul 17;10(7):e0133159. doi: 10.1371/journal.pone.0133159. eCollection 2015. PLoS One. 2015. PMID: 26186592 Free PMC article. Clinical Trial.
-
Clinical application of kampo medicine (rikkunshito) for common and/or intractable symptoms of the gastrointestinal tract.Front Pharmacol. 2015 Jan 30;6:7. doi: 10.3389/fphar.2015.00007. eCollection 2015. Front Pharmacol. 2015. PMID: 25688209 Free PMC article.
-
Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.Cell Death Dis. 2017 Sep 7;8(9):e3040. doi: 10.1038/cddis.2017.436. Cell Death Dis. 2017. PMID: 28880273 Free PMC article.
-
Herbal Therapies in Functional Gastrointestinal Disorders: A Narrative Review and Clinical Implication.Front Psychiatry. 2020 Jul 10;11:601. doi: 10.3389/fpsyt.2020.00601. eCollection 2020. Front Psychiatry. 2020. PMID: 32754057 Free PMC article. Review.
-
The positive role of Chinese herbal medicine as an adjunctive therapy for refractory gastroesophageal reflux disease: A systematic review and network meta-analysis.Medicine (Baltimore). 2025 May 23;104(21):e42565. doi: 10.1097/MD.0000000000042565. Medicine (Baltimore). 2025. PMID: 40419902 Free PMC article.
References
-
- Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence based consensus. Am J Gastroenterol. 2006;101:1900–1920. - PubMed
-
- Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:208–214. - PubMed
-
- Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs. 2007;67:1521–1530. - PubMed
-
- Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton pump inhibitor failure in gastro-oesophageal reflux disease. Where next? Aliment Pharmacol Ther. 2005;22:79–94. - PubMed
-
- Fujimoto K. Review article: prevalence and epidemiology of gastro-oesophageal reflux disease in Japan. Aliment Pharmacol Ther. 2004;20(Suppl 8):5–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous